-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Macrogenics, Raises Price Target to $6

Benzinga·04/20/2026 13:49:38
Listen to the news
Barclays analyst Etzer Darout maintains Macrogenics (NASDAQ:MGNX) with a Overweight and raises the price target from $4 to $6.